Target intelligence / Profile preview

Bacterial 23S ribosomal RNA of the 50S subunit (23S rRNA)

Target
23S rRNA
Molecular classification
Ribosomal RNA (rRNA), Non-coding RNA, Catalytic RNA (ribozyme—peptidyl transferase activity), Component of ribosome (50S subunit of bacterial ribosome)
01

Overview

Bacterial 23S ribosomal RNA of the 50S subunit is a large, non-coding RNA (~2,900 nucleotides in E. coli) that forms the catalytic core of the bacterial large ribosomal subunit (50S). It organizes six secondary structure domains, with domain V housing the peptidyl transferase center—essential for protein synthesis and responsible for peptide bond formation. Numerous antibiotics inhibit bacterial growth by binding to specific sites within 23S rRNA (chiefly in domain V), effectively blocking translation; mutations and modifications in 23S rRNA confer resistance to many classes of antibacterial drugs. Thus, 23S rRNA is critically important both for cell viability and as a therapeutic target for antibiotics. Its molecular architecture and function distinguish it from eukaryotic ribosomes, facilitating selective inhibition by antibiotics.

Other names
23S rRNALarge-subunit ribosomal RNAPeptidyl transferase center RNARibosomal RNA (23S)
02

Mechanism of action

Inhibit peptide bond formation by blocking the peptidyl transferase center; Prevent binding of aminoacyl- or peptidyl-tRNA; Disturb translocation of tRNA and mRNA; Induce ribosomal stalling or premature termination of protein synthesis.

03

Biological functions

Peptidyl transferase activity (catalyzes peptide bond formation)Protein synthesis/TranslationBinding site for tRNAMolecular scaffold for ribosomal proteinsTarget for antibiotic binding
04

Disease associations

Infection (primary antibacterial drug target)Antibiotic resistance (mutations confer resistance to antibiotics targeting the ribosome)Other (essential for bacterial cell viability)
05

Safety considerations

Selective toxicity (drugs must discriminate between bacterial and eukaryotic rRNA—structural differences are exploited but off-target effects possible)Drug resistance from point mutations or methylation of 23S rRNACross-resistance among antibiotics sharing binding domainsPotential effects on human mitochondrial ribosomes for drugs with poor selectivity
06

Interacting drugs

Chloramphenicol

6 more in the full profile.

07

Biomarkers

Mutation analysis of 23S rRNA domains (identifies antibiotic resistance, e.g., macrolide or oxazolidinone resistance)Presence of specific 23S rRNA sequence variants in pathogens (diagnostic for resistant strains)

Beyond the preview

Go deeper on Bacterial 23S ribosomal RNA of the 50S subunit (23S rRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial 23S ribosomal RNA of the 50S subunit (23S rRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call